NCT04456855|UnknownDMC
Locoregional Surgery of the Primary Tumor in de Novo Stage IV Breast Cancer Patients
SYSBTC-001
Loading search results
SYSBTC-001
Sponsor study identifier
observational
358
1 country
3
Study Start
September 1, 2019
Actual (reported)Primary Completion
October 30, 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
July 30, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Current guidelines lack definitive evidences about the relative benefits of locoregional surgery for the primary tumor in de novo stage IV breast cancer. The aim of this study (SYSBTC-001) was to investigate the role of locoregional surgery for primary tumor in de novo stage IV breast cancer.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
July 30, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
September 1, 2019
Actual (reported)July 1, 2020
Actual (reported)July 7, 2020
Actual (reported)October 30, 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
July 30, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Overall survival
The association between locoregional surgery and overall survival (OS), which defined as the time from the beginning of diagnosis of breast cancer to the death with any causes.
5 years
Locoregional progression free survival
5 years
Distant progression free survival
5 years
Patients had pathologically confirmed operable stage IV breast infiltrating carcinoma at initial presentation, and had locoregional surgery for the breast cancer.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Operable stage IV breast cancer patients, whose primary lesion is invasive breast cancer confirmed by pathology, and metastases can be confirmed by pathology or imaginology examination
First People's Hospital of Foshan
Foshan, Guangdong, 528000, China
Sun Yat-Sen Memorial Hospital of Sun Yat-sen
Guangzhou, Guangdong, 510120, China
Yu Y, Hong H, Wang Y, Fu T, Chen Y, Zhao J, Chen P, Cai R, Tan Y, He Z, Ren W, Zhou L, Huang J, Tang J, Ye G, Yao H. Clinical Evidence for Locoregional Surgery of the Primary Tumor in Patients with De Novo Stage IV Breast Cancer. Ann Surg Oncol. 2021 Sep;28(9):5059-5070. doi: 10.1245/s10434-021-09650-3. Epub 2021 Feb 3.
Herui Yao, PhD
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Jun Tang, PhD
Sun Yat-sen University
Guolin Ye, PhD
First People's Hospital of Foshan
First Submitted
July 1, 2020
First Posted
July 7, 2020
Study Start
September 1, 2019
Actual (reported)Primary Completion
October 30, 2020
Estimated (date passed)Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Breast Cancer
Contact the study team to confirm eligibility.
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510120, China
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
July 30, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
July 7, 2020
Record last verified: 2020-07
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: